Formerly known as Juventis, Inc., ArgiNOx Pharmaceuticals, Inc's initial area of research were directed at nitric oxide (NO) which had been shown in Nobel prize-winning research to play a role in a range of physiologic functions. With a paricular focus on treatment of hospitalized patients and organized around discovery and development of drugs for cardiovascular pathologies, the firm's lead compound was Tilarginine Acetate Injection, a synthetically produced endogenous small molecule that inhibits the production of nitric oxide for use in the treatment of heart attack-related cardiogenic shock.
